CBD & Cannabis Dosage Guide Martin A. Lee On May 16, 2018 (Updated on April 1, 2019) https://www.projectcbd.org/how-to/cbd-dosage-guide High dose? Low dose? CBD? THC? Optimizing one's therapeutic use of cannabis may take some experimentation. It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people. Smoking marijuana, however, is not the be-all and end-all of cannabis therapeutics. There are many ways to experience the medical benefits of cannabis, and some of them are even non-intoxicating. In recent years, the advent of potent cannabis oil concentrates, non-intoxicating cannabidiol (CBD) products, [...]
Lire la suitePrenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone Roberto Frau, Vivien Miczán, Francesco Traccis, Sonia Aroni, Csaba I. Pongor, Pierluigi Saba, Valeria Serra, Claudia Sagheddu, Silvia Fanni, Mauro Congiu, Paola Devoto, Joseph F. Cheer, István Katona and Miriam Melis Nature Neuroscience, December 2019, VOL 22, 1975–1985 www.nature.com/natureneuroscience1975 Content courtesy of Springer Nature, terms of use apply. Rights reserved Doi : 10.1038/s41593-019-0512-2 The increased legal availability of cannabis has led to a common misconception that it is a safe natural remedy for, among others, pregnancy-related ailments such as morning sickness. Emerging clinical evidence, however, indicates that prenatal cannabis exposure (PCE) predisposes offspring to various neuropsychiatric [...]
Lire la suiteThe Role of Cannabis within an Emerging Perspective on Schizophrenia Jegason P. Diviant, Jacob M. Vigil, and Sarah S. Stith Medicines, 2018, 5, 86, 1-11. doi : 10.3390/medicines5030086 Abstract Background : Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods : We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results : A review of the literature shows that phytocannabinoid consumption may [...]
Lire la suiteAn update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use Alan J. Budney,· Michael J. Sofis,· Jacob T. Borodovsky European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-018-0976-1 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract : Confusion and controversy related to the potential for cannabis use to cause harm, or alternatively to provide benefit, continues globally. This issue has grown in intensity and importance with the increased recognition of the public health implications related to the escalation of the legalization of cannabis and cannabinoid products. This selective overview and commentary attempt to succinctly [...]
Lire la suiteAssociation Between Marijuana Use and Risk of Cancer. A Systematic Review and Meta-analysis Mehrnaz Ghasemiesfe, Brooke Barrow, Samuel Leonard, Salomeh Keyhani, Deborah Korenstein, JAMA Network Open, 2019, 2, (11), e1916318. doi : 10.1001/jamanetworkopen.2019.16318 Abstract IMPORTANCE : Marijuana use is common and growing in the United States amid a trend toward legalization. Exposure to tobacco smoke is a well-described preventable cause of many cancers; the association of marijuana use with the development of cancer is not clear. OBJECTIVE : To assess the association of marijuana use with cancer development. DATA SOURCES : A search of PubMed, Embase, PsycINFO, MEDLINE, and the Cochrane Library was conducted on June 11, 2018, and updated [...]
Lire la suiteTransdermal Delivery of Cannabidiol Attenuates Binge Alcohol- Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder Daniel J. Liput, Dana C. Hammell, Audra L. Stinchcomb, and Kimberly Nixon Pharmacology, Biochemistry and Behavior, 2013, 111, 120–127. doi : 10.1016/j.pbb.2013.08.013 Abstract Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behavioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alcoholism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In experiment 1, 1.0%, 2.5% and 5.0% CBD gels were evaluated for neuroprotection. [...]
Lire la suiteEfficacy of Ketamine in the Treatment of Substance Use Disorders : A Systematic Review Jennifer L. Jones, Camilo F. Mateus, Robert J. Malcolm, Kathleen T. Brad and Sudie E. Back Frontiers in Psychiatry, 2018, 1-10. doi : 10.3389/fpsyt.2018.00277 Abstract Background : Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective in the treatment of severe depression. Here we review the literature on the efficacy of ketamine in [...]
Lire la suiteUsing CBD to tame a cannabis high? Small doses may have opposite effect Bailey Rahn February 28, 2019 Share Print (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low doses of CBD. CBD can either dampen an out-of-control high [...]
Lire la suiteFDA's Rapid Approval of Esketamine for Severe Depression Questioned Pauline Anderson Medscape, November 13, 2019 https://www.medscape.com/viewarticle/921248 While some experts have hailed intranasal esketamine (Spravato, Janssen) as a "game changer" for treatment-resistant depression (TRD), others are concerned over the US Food and Drug Administration's (FDA) rapid approval of the drug. Dr Erick Turner In an editorial published online October 31 in Lancet Psychiatry, Erick H. Turner, MD, who sits on one of the FDA advisory committees that recommended approval of Spravato, said the drug did not meet standard criteria for FDA approval and that there was little evidence to support its safety and efficacy based on data from [...]
Lire la suiteA Chocolate a Day Keeps Depression Away ? Megan Brooks, Laurie Barclay Medscape, 13 / 09 /2019 https://www.medscape.org/viewarticle/917963 Clinical Context Accumulating evidence suggests that dietary factors, such as eating chocolate, may affect depressive symptoms. The potential mood-enhancing properties of chocolate may relate to its orosensory properties, psychoactive ingredients, and activation of neural reward pathways. However, only a few studies have analyzed associations between chocolate consumption and depressive symptoms, with conflicting results. The goal of this analysis was to evaluate associations between chocolate consumption and depressive symptoms in a large, representative sample of US adults enrolled in the US National Health and Nutrition Examination Survey (NHANES) between [...]
Lire la suite